$7.53−0.20 (−2.59%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
AdaptHealth (AHCO) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue fell 0.5% in FY25, net margin −2.2%.
The four lines that matter · FY21–FY25
Revenue ($M)▼0.5%
3,244.9
FY21→FY25CAGR +7.2%/yr
Net income ($M)—
−70.8
one-off year: see footnoteCAGR —
Free cash flow ($M)▼7.0%
219.4
FY21→FY25CAGR +32.0%/yr
Diluted EPS—
−0.52
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+1.6%
133.0mn → 135.1mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.
Capex
$382.4M
+24.9% YoY in FY25 · 11.8% of revenue.
Returns vs FCF
3%
$7.0M returned vs $219.4M of FCF in FY25. Buybacks + dividends covered by cash flow.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-2¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 18.2% → 18.8%. Net margin -2.2% is below the sector median.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 3,443.3 | 3,244.9 | 3,261.0 | 3,200.2 | 2,970.6 | 2,454.5 | ▼0.5% | +7.2% |
Cost of revenue | 2,898.3 | 2,635.7 | 2,579.9 | 2,576.1 | 2,390.5 | 2,008.9 | ▲2.2% | +7.0% |
Gross profit | 545.0 | 609.2 | 681.1 | 624.1 | 580.1 | 445.6 | ▼10.6% | +8.1% |
Selling, general & admin | 392.7 | 382.3 | 359.2 | 334.6 | 324.8 | 167.5 | ▲6.4% | +22.9% |
Total operating expenses | 874.6 | 518.3 | 417.4 | 1,222.5 | 389.7 | 220.0 | ▲24.2% | +23.9% |
Operating incomefeeds ROC rank | −329.6 | 90.9 | 263.7 | −598.4 | 190.4 | 225.6 | ▼65.5% | −20.3% |
Other income, net | −106.4 | −106.0 | −127.7 | −125.4 | −92.5 | −34.6 | — | — |
Pretax income | −436.0 | −15.2 | 136.0 | −723.8 | 97.9 | 191.0 | — | — |
Income tax | −33.2 | 50.9 | 41.2 | −49.0 | 24.8 | 32.8 | ▲23.4% | +11.6% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −406.7 | −70.8 | 90.4 | −678.9 | 69.3 | 156.2 | — | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −2.98 | −0.52 | 0.61 | −5.31 | 0.33 | 0.67 | — | — |
Diluted shares (mn) | 136.40 | 135.15 | 135.53 | 134.42 | 138.99 | 133.03 | ▼0.3% | +0.4% |
| Margins | ||||||||
Gross margin6th pct in Healthcare | 15.8% | 18.8% | 20.9% | 19.5% | 19.5% | 18.2% | ▼2.1pp | +0.6pp |
Operating margin | −9.6% | 2.8% | 8.1% | −18.7% | 6.4% | 9.2% | ▼5.3pp | −6.4pp |
Net margin36th pct in Healthcare | −11.8% | −2.2% | 2.8% | −21.2% | 2.3% | 6.4% | ▼5.0pp | −8.5pp |
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was 25% vs a 17% norm for this window, likely a one-time item; see the filing.FY23 effective tax rate was 7% vs a 17% norm for this window, likely a one-time item; see the filing.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was AdaptHealth's revenue last fiscal year?
AdaptHealth reported revenue of $3,244.9M in fiscal 2025, down 0.5% from fiscal 2024.
What was AdaptHealth's net income?
AdaptHealth reported net income of −$70.8M in fiscal 2025, a net margin of −2.2%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

